A carregar...

Fragment-based screening of programmed death ligand 1 (PD-L1)

The PD-1 immune checkpoint pathway is a highly validated target for cancer immunotherapy. Despite the potential ad-vantages of small molecule inhibitors over antibodies, the discovery of small molecule checkpoint inhibitors has lagged behind. To discover small molecule inhibitors of the PD-1 pathway...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bioorg Med Chem Lett
Main Authors: Perry, Evan, Mills, Jonathan J., Zhao, Bin, Wang, Feng, Sun, Qi, Christov, Plamen P., Tarr, James C., Rietz, Tyson A., Olejniczak, Edward T., Lee, Taekyu, Fesik, Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6474755/
https://ncbi.nlm.nih.gov/pubmed/30728114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2019.01.028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!